Previous 10 | Next 10 |
home / stock / pxxlf / pxxlf news
Nanobiotix S.A. (NBTX) is expected to report for Q2 2023 Wal-mart de Mexico S A B de C V ADR (WMMVY) is expected to report for Q2 2023 Bion Environmental Technologies Inc. (BNET) is expected to report for Q1 2024 B Communications Ltd (BCOMF) is expected to report for quarter end 2023-...
Poxel (PXXLF) is expected to report for quarter end 2023-06-30
TWYMEEG sales in Japan for the last quarter (April-June) grew 23% over the prior quarter, in line with Sumitomo Pharma’s FY 2023 forecast 1 , which would represent a 90% increase over the prior year sales Company actively pursuing additional financing to initiate ALD Phase 2 Pr...
Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including rare metabolic disorders and non-alcoholic steatohepatitis (NASH) , today announce...
TWYMEEG sales in Japan for the last quarter (April-June) grew 23% over the prior quarter, in line with Sumitomo Pharma’s FY 2023 forecast 1 , which would represent a 90% increase over the prior year sales Company actively pursuing additional financing to initiate ALD Phase 2 Pr...
Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced...
This program rewards companies innovating on strategic themes for French sovereignty Additional evidence of the technological value of Poxel's assets Regulatory News: POXEL SA (Euronext: POXEL – FR0012432516), a clinical stage biopharmaceutical company developin...
Regulatory News: POXEL SA (Euronext: POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, announce...
Shareholders approved all proposed resolutions by the Board of Directors Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysi...
Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced...
News, Short Squeeze, Breakout and More Instantly...
Poxel SA Company Name:
PXXLF Stock Symbol:
OTCMKTS Market:
TWYMEEG ® gross sales in Japan for Sumitomo Pharma Fiscal Year 2023 1 reached JPY 4.6 billion (EUR 27.9 million) 2 , exceeding guidance 3 by more than 8% TWYMEEG ® ’s FY 2024 forecast 4 of JPY 11.3 billion (EUR 69.1 million 2 ) would represent ...
TWYMEEG gross sales in Japan should exceed its FY 2023 1 guidance 2 of JPY 4.2 billion (EUR 25.7 million) 3 driven by a favourable sales trend in Japan. Sumitomo Pharma to report full year results on May 14 th , 2024 Company expects TWYMEEG’s FY 2024 4 forecast ...
Exclusive discussions and finalization of related documentation underway with a leading investor to monetize royalties from TWYMEEG ® (Imeglimin) sales in Japan Cash runway estimated to be sufficient until the completion of the transaction expected by the end of April, including ...